Arbutus Biopharma Corp (NAS:ABUS)
$ 4.04 -0.01 (-0.25%) Market Cap: 762.68 Mil Enterprise Value: 624.18 Mil PE Ratio: 0 PB Ratio: 6.22 GF Score: 51/100

Arbutus Biopharma Corp to Discuss the New Data Being Presented at EASL - Conference Call Transcript

Jun 28, 2021 / 12:00PM GMT
Release Date Price: $3.37
Operator

Good morning, ladies and gentlemen, and welcome to the Arbutus Biopharma Corporation EASL 2021 presentation review conference call. (Operator Instructions) As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Ms. Pam Murphy. Please go ahead.

Pam Murphy
Arbutus Biopharma Corporation - IR Consultant

Thank you, and good morning. Hopefully, everyone has been able to connect to EASL presentation review webcast and you're able to access the slides. The slides are also available in PDF form under the Investors section of Arbutus' website at www.arbutusbio.com.

With me today from the Arbutus executive team are Bill Collier, President and Chief Executive Officer; Dr. Gaston Picchio, Chief Development Officer; Dr. Micheal Sofia, Chief Scientific Officer; and Dave Hastings, Chief Financial Officer.

Bill will begin with a quick summary of the EASL presentation followed by Gaston, who will then walk you through the highlights of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot